scout

Roy Herbst, MD, PhD, Yale Cancer Center

Articles by Roy Herbst, MD, PhD, Yale Cancer Center

Biomarkers for Immunotherapy in Resectable NSCLC

ByMark A. Socinski, MD, AdventHealth Cancer Institute,Martin Dietrich, MD, PhD,Roy Herbst, MD, PhD, Yale Cancer Center,Chaitali Nangia, MD, Patty and George Hoag Cancer Center,Sandip P. Patel, MD, University of California San Diego,Neal Edward Ready, MD, PhD, Duke Medical Center

Dr Roy S. Herbst comments on the utilization of biomarkers and information needed to help aid in treatment decisions about perioperative therapy for patients with resectable non–small cell lung cancer.

Atezolizumab After Adjuvant Chemotherapy in Resectable NSCLC

ByMark A. Socinski, MD, AdventHealth Cancer Institute,Martin Dietrich, MD, PhD,Roy Herbst, MD, PhD, Yale Cancer Center,Chaitali Nangia, MD, Patty and George Hoag Cancer Center,Sandip P. Patel, MD, University of California San Diego,Neal Edward Ready, MD, PhD, Duke Medical Center

Dr Martin Dietrich comments on the IMpower010 trial of atezolizumab versus best supportive care after adjuvant chemotherapy in patients with resected non–small cell lung cancer.

Clinical Endpoints and Neoadjuvant Therapy for Resectable NSCLC

ByMark A. Socinski, MD, AdventHealth Cancer Institute,Martin Dietrich, MD, PhD,Roy Herbst, MD, PhD, Yale Cancer Center,Chaitali Nangia, MD, Patty and George Hoag Cancer Center,Neal Edward Ready, MD, PhD, Duke Medical Center,Sandip P. Patel, MD, University of California San Diego

The impact of endpoints used in clinical trials of neoadjuvant therapy for resectable non–small cell lung cancer as they relate to newer drug approvals and real-world practice.

Neoadjuvant Immunotherapy for Resectable NSCLC

ByMark A. Socinski, MD, AdventHealth Cancer Institute,Martin Dietrich, MD, PhD,Roy Herbst, MD, PhD, Yale Cancer Center,Chaitali Nangia, MD, Patty and George Hoag Cancer Center,Sandip P. Patel, MD, University of California San Diego,Neal Edward Ready, MD, PhD, Duke Medical Center

Martin Dietrich, MD, PhD, describes his interpretations of the KEYNOTE-799 study of pembrolizumab plus chemoradiation therapy for unresectable stage III non–small cell lung cancer.

Latest Updated Articles